BackgroundImmunotherapy combined with chemotherapy has improved outcomes in advanced gastric cancer (GC), but reliable biomarkers to predict clinical benefit remain limited. Metabolomics provides a co
aaccuracy of the mass measurement, as represented by the difference between the calculated and the measured accurate mass, expressed in ppm of calculated mass.bratio of the mean mass signal intensitie
Average [median (IQR)] substrate utilisation pre- and post-expedition for the energy expenditure during the two periods of sleep, SMR-1 and SMR-; raw and normalised to lean tissue weight.
